Companies › Bracco Diagnostics
1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 4, 1 Phase 2; Neurology, Cardiovascular, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sulfur Hexafluoride Lipid Type A Microspheres (Lumason) Ultrasound contrast agent | – | Phase 3 | Heart Diseases; Trauma Abdomen; Hydrocephalus in Infants | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06400004 | Sulfur Hexafluoride Lipid Type A Microspheres (Lumason) | Phase 3 | Heart Diseases | Cardiovascular | Dec 2026 |
| NCT03490929 | Sulfur Hexafluoride Lipid Type A Microspheres (Lumason) | Phase 4 | Trauma Abdomen | Other | Dec 2026 |
| NCT06693752 | Sulfur Hexafluoride Lipid Type A Microspheres (Lumason) | Phase 2 | Hydrocephalus in Infants | Neurology | Sep 2027 |
No annotated target.
–
CSPC Mingfule Pharmaceutical (Guangzhou) Epygenix RHEACELL GmbH & Co. KG Shenzhen Ausa Pharmed Tenax Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.